EUVIMEDEUVIMED entdecken
Crossref

A Dibenzo- p -dioxin-Shaped New Chemotype of Glycopeptide Antibiotic Active against Drug-Resistant Pathogens

Xingkun Li, Mengru Wang, Lixin Yin, Jiawei Cao, Rui Wang, Xinzhu Wang, Qian Chen, Dexi Bi, Zhilong Zhao, Zixin Deng, Anwei Hou, Min Xu iD

ACS Infectious Diseases · 12.06.2026 · 12 (6) · 1936-1946

DOI: 10.1021/acsinfecdis.6c00042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 21.05.2026. Verfasst von Xingkun Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Center of Technology Innovation for Synthetic Biology, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, West 7th …. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Glycopeptides, Streptomyces. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China, Natural Science Foundation of Tianjin Municipality, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glycopeptide antibiotics (GPAs) are the drugs of "last resort" for treating multidrug-resistant Gram-positive infections such as methicillin-resistant Staphylococcus aureus and enterococci. Unfortunately, GPAs are vulnerable to resistance and the dissemination of various types of vancomycin-resistant determinants warrants the discovery of GPAs with novel chemical structures and modes of action (MOA). The overlooked GPAs from the type V subgroup adopt a unique MOA by interrupting cell wall remodeling and are promising lead candidates in antibiotic development. Herein, we describe the discovery of fumamycin from Streptomyces fumanus CGMCC 4.1732 through phylogenetic-guided genome mining and heterologous expression. Fumamycin is the first decapeptide scaffold GPA free of the conserved 4-hydroxyphenylglycine (Hpg) and tryptophan residues, and its peptide scaffold is cross-linked through a unique biaryl ether bond between two 3,5-dihydroxyphenylglycine (Dpg) residues at positions 1 and 3 in the decapeptide scaffold, and in particular, an unprecedented dibenzo-p-dioxin ring between tyrosine at position 6 (Tyr6) and Dpg at position 9 (Dpg9). Gene disruption determines the two P450s, FumD and FumE, are responsible for constructing the dibenzo-p-dioxin ring and the Dpg1-O-Dpg3 cross-link, respectively. Fumamycin represents a new-to-nature GPA chemotype beyond the existing type I-V GPA classification system, it inhibits bacterial growth through a similar manner to that of type V GPAs by binding to peptidoglycan and blocking the activity of autolysins, suggesting a conserved MOA distinct from type I-IV GPAs that inhibit cell wall biosynthesis by binding to d-Alanyl-d-Alanine motif in lipid II, and providing new lead compounds for developing antibiotics to mitigate antimicrobial resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsGlycopeptidesStreptomycesMicrobial Sensitivity TestsDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

antimicrobial resistancedrug discoveryglycopeptide antibioticnatural productsstreptomycessynthetic biology

Substanzen

Anti-Bacterial AgentsGlycopeptides

Autor:innen und Institutionen

  • National Center of Technology Innovation for Synthetic Biology, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, West 7th Avenue No. 32, Tianjin 300308, China.
  • Haihe Laboratory of Synthetic Biology, West 15th Avenue No. 21, Tianjin 300308, China.
  • University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China.
  • School of Chemistry and Chemical Engineering, Linyi University, Linyi, Shandong 276000, China.
  • Department of Functional Intestinal Diseases, General Surgery of Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
  • College of Pharmacy, Linyi University, Linyi, Shandong 276000, China.

ORCID-Profile: Min Xu

Förderung

  • Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China
  • Natural Science Foundation of Tianjin Municipality
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Chinese Academy of Sciences
  • Haihe Laboratory of Synthetic Biology
  • Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project
  • Agilent University Relations: ACT-UR Program

Zitieren

APA

Li, X., Wang, M., Yin, L., Cao, J., Wang, R., Wang, X., Chen, Q., Bi, D., Zhao, Z., Deng, Z., Hou, A., & Xu, M. (2026). A Dibenzo- p -dioxin-Shaped New Chemotype of Glycopeptide Antibiotic Active against Drug-Resistant Pathogens. ACS Infectious Diseases, 12(6), 1936-1946. https://doi.org/10.1021/acsinfecdis.6c00042

Vancouver

Li X, Wang M, Yin L, Cao J, Wang R, Wang X, et al. A Dibenzo- p -dioxin-Shaped New Chemotype of Glycopeptide Antibiotic Active against Drug-Resistant Pathogens. ACS Infectious Diseases. 2026;12(6):1936-1946. doi:10.1021/acsinfecdis.6c00042

BibTeX
@article{Li2026,
  author = {Li, Xingkun and Wang, Mengru and Yin, Lixin and Cao, Jiawei and Wang, Rui and Wang, Xinzhu and Chen, Qian and Bi, Dexi and Zhao, Zhilong and Deng, Zixin and Hou, Anwei and Xu, Min},
  title = {A Dibenzo- p -dioxin-Shaped New Chemotype of Glycopeptide Antibiotic Active against Drug-Resistant Pathogens},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {6},
  pages = {1936--1946},
  doi = {10.1021/acsinfecdis.6c00042}
}
Kostenlos starten →